Sanofi SNY announced positive data from the phase III LUNA 3 study, which evaluated its covalent BTK inhibitor, rilzabrutinib, for treating patients with immune thrombocytopenia (ITP), an autoimmune ...
Source LinkSanofi SNY announced positive data from the phase III LUNA 3 study, which evaluated its covalent BTK inhibitor, rilzabrutinib, for treating patients with immune thrombocytopenia (ITP), an autoimmune ...
Source Link
Comments